TY - JOUR
T1 - Addressing the current challenges of non-small-cell lung cancer clinical trial accrual
AU - Curran, Watter J.
AU - Schiller, Joan H.
AU - Wolkin, Allan C.
AU - Comis, Robert L.
N1 - Funding Information:
The Coalition of Cancer Cooperative Groups (CCCG) convened a 1-day program entitled Addressing the Current Challenges of Non–Small-Cell Lung Cancer (NSCLC) Clinical Trial Accrual (June 20, 2007; Dallas, Texas) to develop specific strategies for enhancing accrual into clinical trials and to increase and sustain the level of discussion with and among cooperative group– and community-based researchers. Attendees included members of the National Cancer Institute (NCI), Scientific Leadership Council (SLC), advocates in lung cancer, and CCCG Board of Directors and Patient Advisory Board; investigators representing the priority trials in NSCLC; Community Clinical Oncology Program (CCOP) representatives; and leaders from the industry. Recommendations from the
PY - 2008/7
Y1 - 2008/7
N2 - Conducting research in patients with non - small-cell lung cancer (NSCLC) is challenging, primarily because of low patient accrual rates resulting from patient-, physician-, protocol-, and healthcare system-related barriers. The Coalition of Cancer Cooperative Groups convened a 1-day program entitled Addressing the Current Challenges of NSCLC Clinical Trial Accrual to develop specific strategies for enhancing accrual into NSCLC clinical trials and to increase and sustain the level of discussion with and among cooperative group and community-based researchers. Some of the important areas that were highlighted at the meeting included predictors of successful and unsuccessful trial accrual based on 6 NSCLC trials, of which 4 were considered high-priority NSCLC trials; issues surrounding the process of clinical trial activation; and the role of patient advocates in enhancing trial accrual. Efforts by multidisciplinary teams comprising clinical and laboratory researchers, patient advocates, governmental agencies, and private industries are needed to improve NSCLC trial activation and accrual, with a focus on commitment to ongoing communication among all constituents, measures to improve the activation process, and increased study awareness at the community oncology and patient levels.
AB - Conducting research in patients with non - small-cell lung cancer (NSCLC) is challenging, primarily because of low patient accrual rates resulting from patient-, physician-, protocol-, and healthcare system-related barriers. The Coalition of Cancer Cooperative Groups convened a 1-day program entitled Addressing the Current Challenges of NSCLC Clinical Trial Accrual to develop specific strategies for enhancing accrual into NSCLC clinical trials and to increase and sustain the level of discussion with and among cooperative group and community-based researchers. Some of the important areas that were highlighted at the meeting included predictors of successful and unsuccessful trial accrual based on 6 NSCLC trials, of which 4 were considered high-priority NSCLC trials; issues surrounding the process of clinical trial activation; and the role of patient advocates in enhancing trial accrual. Efforts by multidisciplinary teams comprising clinical and laboratory researchers, patient advocates, governmental agencies, and private industries are needed to improve NSCLC trial activation and accrual, with a focus on commitment to ongoing communication among all constituents, measures to improve the activation process, and increased study awareness at the community oncology and patient levels.
KW - Cooperative group
KW - Enrollment recommendations
KW - Participation
KW - Patient advocates
KW - Study activation
UR - http://www.scopus.com/inward/record.url?scp=49249095150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49249095150&partnerID=8YFLogxK
U2 - 10.3816/CLC.2008.n.033
DO - 10.3816/CLC.2008.n.033
M3 - Article
C2 - 18650170
AN - SCOPUS:49249095150
SN - 1525-7304
VL - 9
SP - 222
EP - 226
JO - Clinical lung cancer
JF - Clinical lung cancer
IS - 4
ER -